Sherbrooke’s Immune Biosolutions claims its drug neutralizes COVID-19

Inhalation immunotherapy is currently in Phase 1 and 2 clinical trials.

Content of the article

SHERBROOKE – Sherbrooke-based company Immune Biosolutions says it has developed a biologic drug candidate that is “capable of neutralizing SARS-CoV-2 (COVID-19) and all of its worrying current variants that have emerged throughout the pandemic , including the latest Omicron variant.

Leave a Comment